Together for medicines that matter
Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

Non-IFRS Measures

This presentation contains references to certain non-IFRS measures including EBITDA and Adjusted EBITDA, each of which are not recognized under International Financial Reporting Standards (“IFRS”). The Company believes that non-IFRS financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-IFRS financial information to supplement their IFRS results. The non-IFRS financial information is presented for supplemental informational purposes only, and should not be considered a substitute for financial information presented in accordance with IFRS, and may be different from similarly titled non-IFRS measures used by other companies. EBITDA and Adjusted EBITDA each have limitations as an analytical tool, respectively, and you should not consider any of these measures either in isolation or as a substitute for other methods of analyzing the results as reported under IFRS. Our management team uses these non-IFRS financial measures to evaluate our profitability and efficiency, to compare operating results to prior periods, and to measure and allocate financial resources internally. However, management does not consider such non-IFRS measures in isolation or as an alternative to measures determined in accordance with IFRS. See appendix to this presentation for a reconciliation of Adjusted EBITDA to the nearest GAAP measure.
Agenda

Unique business strategy and capabilities to improve efficiency

Precision medicine platforms to improve probability of success

Building a strong growth business and a large royalty pool
Unique strategy and capabilities to improve Efficiency & Probabilities of Success
# Together for medicines that matter

Who we are and what we do

<table>
<thead>
<tr>
<th>Purpose</th>
<th>Together for medicines that matter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focus</td>
<td>We aspire to impact patients’ lives by</td>
</tr>
<tr>
<td></td>
<td>• PanOmics-driven drug discovery for effective medicines</td>
</tr>
<tr>
<td></td>
<td>• iPSC-based Cell Therapies for cures</td>
</tr>
<tr>
<td></td>
<td>• Just – Evotec Biologics; continuous manufacturing of biologics for better access</td>
</tr>
<tr>
<td>End-to-end Shared R&amp;D</td>
<td>• Our role in the industry is to discover, develop and manufacture medicines that matter together with our partners</td>
</tr>
<tr>
<td></td>
<td>• We select solutions, propelled forward by the passion of our people striving for the fastest ways to impact patients’ lives. We apply the essential convergent technologies, along the world-leading end-to-end shared R&amp;D continuum.</td>
</tr>
</tbody>
</table>
We design medicines for difficult to treat diseases in efficient collaborations. We focus on data driven precision medicine and early disease relevance to improve Probabilities of Success. We built the “shared economy” in R&D, designed to result in a large royalty pool.

„The goal of Evolution is not one single human, it is mankind.“

Manfred Eigen
1927–2019, Co-founder of Evotec, Nobel Prize 1967
Panomics and tech convergence bring up Probability of Success

Current challenges in R&D

Key challenges

- **R&D model is inefficient**
  - Challenging returns due to “too late and “expensive failure”

- **“One drug fits all” is outdated**
  - 90% of drugs are efficacious only in 50% of patients

- **New modalities did not solve all problems**
  - 9% of Phase I biologics receive approval\(^2\)

- **Emerging technologies are still very fragmented**
  - Precision medicine toolkit, OMICS platforms, and AI/ML

Development costs per asset increase

- Cost per asset doubled since 2010, in US$ m
  - 2010: 1,188
  - 2020: 2,500
  - Increase: +100%

Commercial returns decrease

- IRR since 2010\(^1,4\)
  - 2010: ~10
  - 2020: ~2
  - Decrease: -80%

---

\(^1\) IRR = Internal Rate of Return
\(^3\) excl. Covid-19 vaccines
\(^4\) Sources: Debante – Centre for Health Solutions: Ten years on measuring the return of pharmaceutical innovation 2020; Evaluate Pharma – World Preview 2018 / World Preview 2020
Significant improvements of Probability of Success are possible

How we can improve Probability of Success (PoS) in early R&D (Examples/simplified)

**Target identification**
System biology to better understand diseases e.g. associating existing targets with new diseases

**Lead optimisation**
*In silico* classification of targets via computational chemistry e.g. better prioritised drugs accelerated

**Trial design**
Understanding sub populations via biomarkers e.g. better patient stratification

**Todays use of AI/ML**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Data integration</th>
<th>Efficacy &amp; safety predictions</th>
</tr>
</thead>
<tbody>
<tr>
<td>iPSC driven disease relevance</td>
<td>~10%</td>
<td></td>
</tr>
<tr>
<td>Molecular data &amp; patient stratification</td>
<td>~10%</td>
<td></td>
</tr>
<tr>
<td>‘Standard’ success for discovery project</td>
<td>~10%</td>
<td></td>
</tr>
<tr>
<td>Data aggregation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Many players at work to initiate a new “data driven” industry paradigm.

Still a highly fragmented industry

Selected AI/ML companies (Industry landscape – Illustrative & highly simplified)
Convergence of precision medicine platforms to improve probability of success
Precise medicines with omics, cell therapy & tech convergence

Overview & focus areas to accelerate leadership and profitable growth

PanOmics

iPSC-based Cell Therapies

Just – Evotec Biologics

End-to-end Shared R&D

Data-driven R&D Autobahn to Cures

From disease understanding to precise medicines

Industry leading iPSC capability at scale for off the shelf solutions

Disruptive technology to offer lowest cost, highest quality biologics

Multi-modality end-to-end shared drug discovery & development
Expanded and new alliances with precision medicine platforms

Most significant alliances signed in 9M 2022

<table>
<thead>
<tr>
<th>PanOmics</th>
<th>iPSC-based Cell Therapies</th>
<th>Just – Evotec Biologics</th>
<th>End-to-end Shared R&amp;D</th>
</tr>
</thead>
</table>

Data-driven R&D Autobahn to Cures

<table>
<thead>
<tr>
<th>Alliance</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehringer Ingelheim</td>
<td>Ophthalmology; iPSC- and EVOpanOmics; Undisclosed upfront and milestone payments, layered royalties</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Neurodegeneration; iPSC and expansion on target protein degradation</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Target protein degradation / molecular glues; EVOpanOmics &amp; EVOpanHunter; € 200 m upfront, € 5 bn deal value, tiered royalties</td>
</tr>
<tr>
<td>Lilly</td>
<td>Kidney diseases &amp; diabetes; E.MPD; EVOpanOmics; Undisclosed upfront payment; Five programmes with milestone payments of up to US$180 preprogramme, tiered royalties</td>
</tr>
<tr>
<td>Janssen</td>
<td>Protein homeostasis; TargetAlloMod; €210 m milestone payment per project, tiered royalties</td>
</tr>
</tbody>
</table>
Early disease relevance and understanding changes paradigm

Molecular disease profiles and AI/ML drive paradigm shift\(^1\)

---

**Current paradigm**

**Target driven**

- **Drug screening**
  - Target
- **Drug optimisation**
  - Efficacy
- **IND enabling**
  - Safety
- **Clinical development**
  - Disease relevance
  - Only 50% of patients treated efficiently\(^2\)

---

**Omics paradigm**

**Molecular profile-driven**

- **Disease relevance**
- **Drug likeness**
- **Confirmatory safety**
- **Confirmatory disease relevance**

---

14 years

---

8 years

---


\(^{2}\) Regulatory Toxicology and Pharmacology; Volume 32, Issue 1, August 2000; Pages 56–67; Journal of Health Economics Volume 47, May 2016, Pages 20-33; Clinical development success rates for investigational drugs; Nature Biotechnology volume 32, pages40–5(2014); Evotec estimates
Enabling the power of precision medicine in drug discovery

Patient-centric drug discovery platforms for lower attrition rates and safer drugs

<table>
<thead>
<tr>
<th>Target ID / validation</th>
<th>Hit identification</th>
<th>Lead optimisation</th>
<th>Pre-clinical development</th>
<th>Clinical phase I/II/III</th>
<th>Approval</th>
<th>Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target ID / validation</td>
<td>Novel targets &amp; pathways</td>
<td>iPSC disease models</td>
<td>Phenotype reversion screening</td>
<td>Co-culture models</td>
<td>Safety testing</td>
<td>Clinical trial in a dish’</td>
</tr>
</tbody>
</table>

**Patient databases with clinical and molecular profiles**

**EVOpanOomics**
Data generation

**EVOpanHunter**
Data analysis

**Disease signature**

**Control**

**Patient stratification**

**Biomarker discovery**

**ML / AI based prediction**

**Novel cures for patients**

PoS = probability of success
Integrated approach for deeper understanding of disease

Unprecedented molecular characterization of disease results in 1st in class treatments
### E.MPD core component of alliances in CKD

CKD strategic drug discovery deals

<table>
<thead>
<tr>
<th>Year</th>
<th>Partner</th>
<th>Upfront</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016/17</td>
<td>CSL Vifor</td>
<td>Vifor funded: € 25 m</td>
</tr>
<tr>
<td>2018/19</td>
<td>CSL Vifor</td>
<td>Vifor funded: € 25 m</td>
</tr>
<tr>
<td>2020</td>
<td>CSL Vifor</td>
<td>Vifor funded: € 25 m</td>
</tr>
<tr>
<td>2021</td>
<td>CSL Vifor</td>
<td>Vifor funded: € 25 m</td>
</tr>
<tr>
<td>2022</td>
<td>CSL Vifor</td>
<td>Vifor funded: € 25 m</td>
</tr>
</tbody>
</table>

**Milestones**
- > € 300 m per product (2016/17)
- > € 150 m per product (2018/19, 2020, 2021, 2022)

**Research funding**
- 50% on all projects (2016/17)

**Tiered royalties**

**JV: NepThera**

From Target identification & validation, via biomarker identification, to patient stratification
Deep understanding of biology with molecular signatures

Molecular Patient Database (E.MPD)

Patient databases with clinical and molecular profiles

**EVO\textsuperscript{pan}Omics**
Data generation

**EVO\textsuperscript{pan}Hunter**
Data analysis

- Multiple rare diseases
- Tuber-
culosis
- Liver
disease
- Infectious
diseases
- Autoimmune
disease
- Fibrosis
- Inflammation
- Lung & Multiple
cancers
- Kidney
diseases
- CNS
- Womens’
Health
- Tuber-
culosis
- Liver
disease
- Infectious
diseases
- Autoimmune
disease
- Fibrosis
- Inflammation
- Lung & Multiple
cancers
- Kidney
diseases
- CNS
- Womens’
Health

EVO\textsuperscript{pan}Omics: Genomics, Transcriptomics, Proteomics and Metabolomics
EVO\textsuperscript{pan}Hunter: Bioinformatics, AI/ML
Protein degradation partnership with BMS becomes strategic

Using EVOpanOmics & EVOpanHunter – Quantum Leap in 2022

Proteomics approach to targeted protein degradation
Development of novel therapies for a broad range of diseases

- Upfront US$ 65 m
- Potential milestones > US$ 250 m per project
- Double-digit royalties

May 2020 Screening milestone
Oct 2020 Project initiation
Mar 2021 Double-digit million extension
June 2021 New collaboration in undisclosed therapeutic area

May 2022
8-year extension
Upfront $ 200 m
Deal value > $ 5bn

2018
2019
2020
2021
2022

June 2020
US$ 10 m – Expansion
Dec 2020
Second project initiation
May 2021
Third project initiation

2018 2019 2020 2021 2022
iPSC already highly productive, …”but just the beginning”

Continuous expansion of disease models and programs to result in new collaborations

Proof of concept in iPSC drug discovery from target ID to clinical development shown for Neurodegenerative Diseases
Delivering health by expanding & improving cell therapy research
Overview 9M 2022

- E.iBETA – First generation cell therapy for Insulin-dependent diabetes
- iPSC-based beta cells combined with Cell Pouch™

- Acquisition of Rigenerand Srl, Medolla, Italy, now operating as Evotec (Modena) Srl
- Evotec Cell Accelerator: cGMP manufacturing as basis for off-the-shelf cell therapies
Transformative iPSC-based disease modelling & cell therapy

Industry leading iPSC platform

Global precision medicine market in US$ bn

- 2020: 63
- 2025: 107
- CAGR ~11%

Global cell therapy market in US$ bn

- 2020: 7.8
- 2025: 15.7
- CAGR ~15%

Global induced pluripotent stem cell (iPSC) Market in US$ bn

- 2020: 1.6
- 2025: 2.3
- CAGR ~7%

“IPS cells are a powerful tool to cure intractable diseases because they can be made from patients’ somatic cells.”
Shinya Yamanaka, Nobel prize laureate

“Disease in a dish” & Screening

iPSC platform

iPSC-derived cell types

Off-the-shelf cell therapeutic

Patient or healthy donor

“IPS cells are a powerful tool to cure intractable diseases because they can be made from patients’ somatic cells.”
Shinya Yamanaka, Nobel prize laureate

Largest and most sophisticated iPSC platform in the industry

- >300 patient-derived cell lines across 15+ disease areas

Optimized for high reproducibility, high throughput and robustness

First iPSC-derived drug candidate entered clinical trials in 2021

EVOcells – Seamlessly integrating discovery, development and cGMP manufacturing

---

1) https://www.gminsights.com/ Feb 2020, Evotec estimates
2) https://www.grandviewresearch.com/industry-analysis/cell-therapy-market, Evotec estimates
3) https://www.researchandmarkets.com/reports/4805485/induced-pluripotent-stem-cell-ips-global
# Building a iPSC-based cell therapy pipeline

## Internal off-the-shelf cell therapy programmes

<table>
<thead>
<tr>
<th>Field</th>
<th>Program / Project</th>
<th>Disease area</th>
<th>Exploratory</th>
<th>Pre-clinical research</th>
<th>Pre-clinical development</th>
<th>IND / Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-tumour cell therapy</strong></td>
<td>iNK</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iM</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>γδ iT</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>αβ iT</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Regenerative therapy</strong></td>
<td>E.I.BETA Sernova Cell Pouch™</td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iCM</td>
<td>Heart failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune-modulation</strong></td>
<td>iMSCs, iMSC exosomes</td>
<td>Various</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iNK, iTreg</td>
<td>Anti-fibrotic, auto-immune</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### iPSC-based cell types

- **iNK**: Natural killer cells
- **iT**: αβ and γδ T cells
- **iM**: Macrophages
- **iBeta**: Pancreatic islets
- **iCM**: Cardiomyocytes
- **iMSC**: Mesenchymal stromal cells

† Immuno-oncology
Paradigm shift in biologics starting its market entry strategy

Just – Evotec Biologics development update

- Just – Evotec Biologics is in its build up and initial investment phase
- Discovery and pre-clinical programs build a robust pipeline towards commercial contracts

Ground-breaking for second new biologics facility J.POD® Toulouse
TOGETHER with our partners for access
Our mission realized through partnerships

Design and apply innovative technologies to dramatically expand global access to biotherapeutics

1. **Access** to Innovative molecules
2. **Access** to biosimilars
3. **Access** to pandemic preparedness
### Disease area and No. of programmes

<table>
<thead>
<tr>
<th>Disease area</th>
<th>Discovery</th>
<th>J.MD™ Optimization</th>
<th>Pre-clinical Development</th>
<th>Clinical Manufacturing</th>
<th>Commercial Manufacturing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious diseases</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other / undisclosed</td>
<td>ND¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Broad basis for sustained growth

- >15 partners / >20 programmes
- 3 programmes added in Q3 and one more DOD award in Q4
- Continued emphasis on optimal value mix of
  - Fee for service
  - EVOroyalty
  - EVOequity
- Better access to affordable medicine for all
  - >50% of programmes addressing targets set to reach UN SDG 3²)

¹) Not Disclosed
²) United Nations SustA.I.nable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages
Annual sales have already tripled versus FY21

Biologics sales order book

Just – Evotec Biologics

Closed Sales, Sales in € m

31

>90

2021

2022¹)

3x

Key progress

since half year results

Closed sales is leading indicator of future 2023 and 2024 revenues

Closed sales 2022 sales show strong growth – indicates market entry progressing and future potential

Business Development is ramping up further to maximize partnering opportunities, particularly in U.S. and Europe

- Secured and initiated new anti-Plague mAb development program in Q3 (up to US$ 49.9 m over 5 years)

- Launched commercial process development activities in Q3

- Undisclosed biosimilar partner

- Kicked off

¹) YTD as of end Sept 2022
Continued strong performance of shared R&D platform

Latest highlights in 9M 2022

• Several new and extended integrated drug discovery agreements e.g., Viotika, …
• Continued increased demand for integrated CMC (Chemistry, Manufacturing and Control) capabilities e.g., Zogenix, …
• Successful achievement of four performance-based small milestones within existing partnerships; e.g., IND submission, pre-clincial development candidate nomination, and lead optimisation start
• Strong performance of DMPK / ADME-tox testing, e.g., UCB, …
Clear path to the market for rare diseases & precision medicine

Complementing our Abingdon, UK and Verona, Italy API Capabilities

## Combined high-end capabilities
- Chemical and Analytical Development teams with strong track record
- State-of-the-art laboratory equipment
- GMP labs and kilo lab facilities
- 3 GMP pilot plants (18 reactors from 100 to 1,600L, 7 m³)
- Commercial API manufacturing capacity

## EU GMP certified facility
- ~60 chemical manufacturing experts
- EU cGMP certified and provides highly flexible drug substance manufacturing space with over 5,000 square metres
- Highly flexible product lifecycle management strategies, particularly in rare diseases
Building a strong growth business and a large royalty pool
Significant expansion of alliances is basis for long-term success

Attraction, Extension, Retention

**Attraction**

- Customer base more diversified; revenues have grown significantly

**Extension**

- Integrated drug discover & development offering yields increasing “share of wallet”
- Faster and better results versus in-house infrastructures

**Structural Retention ≥90%**

- Solid customer retention rates
- Strong basis for double-digit growth
Co-ownership leading to value creation upside
High-value partnerships offer path to increased royalties

Co-owned biologics pipeline assets

<table>
<thead>
<tr>
<th>Year</th>
<th>Projects</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>0</td>
</tr>
<tr>
<td>2021</td>
<td>&gt;20</td>
</tr>
<tr>
<td>2025</td>
<td>&gt;40</td>
</tr>
</tbody>
</table>

2025 expected

Business model for Just - Evotec Biologics

- **“CDMO-model”**
  - Revenues
    - > € 250 m
  - Utilisation from third party contracts
    - ~60%

- **“Co-ownership” model**
  - Value creation from co-owned projects via milestones & royalties
    - ~80%
  - Revenues
    - < € 250 m

1) Including EVOequity holdings
The growing iceberg of EVT Innovate product opportunities

>220 projects including EVOequity and BRIDGEs: ~180 in partnerships, >40 internal R&D

<table>
<thead>
<tr>
<th>Neurosciences &amp; Pain</th>
<th>Oncology</th>
<th>Metabolic Diseases</th>
<th>Inflammation &amp; Immunology</th>
<th>Virology</th>
<th>Anti-bacterial</th>
<th>Global Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preclinical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H2L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD/Scr.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Partnered Pipeline** | **Unpartnered Pipeline** | **Equity Pipeline** | **BRIDGEs Pipeline** | **Integrated Drug Discovery**

1) Also includes Women’s Health, Respiratory projects
The Equity Pipeline does not contain programs from EVT/partners that are not publicly disclosed
“Evotec Inside”

Steady stream of high-value catalysts

Selected pipeline events within next 12 – 24 months
- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Phase II data with Bayer in DNP (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Kazia in Oncology (EVT801)
- Phase Ib / II initiation of Exscientia in Oncology (EXS21546)
- Phase I initiation in Covid-19 / HBV (EVT075)
- Phase I initiation with Bayer in Kidney diseases
- Phase I initiations with Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I initiation with BMS in Oncology
- Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, …)

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Therapeutic Area / Indication</th>
<th>Partner</th>
<th>Discovery</th>
<th>Pre-clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>SKYCovione</td>
<td>COVID-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT201</td>
<td>Insomnia (GABA-A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAY2395840</td>
<td>Diabetic Neuropathic Pain (B1)</td>
<td>Carnick</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT7001</td>
<td>Oncology (CDK7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XP-105</td>
<td>Oncology (mTORC1/2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT401</td>
<td>Immunology &amp; Inflammation (P2X7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAY2328065</td>
<td>Gynaecology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXS21546</td>
<td>Oncology (various programmes)</td>
<td>Exscientia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GNTX 6016</td>
<td>Pain (GB2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT894</td>
<td>Chikungunya (Antibody)</td>
<td>SANOFI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Disclosed</td>
<td>Neuroscience &amp; Pain</td>
<td>n.a.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not Disclosed</td>
<td>Neuroscience &amp; Pain</td>
<td>n.a.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT801</td>
<td>Oncology (VEGFR3)</td>
<td>KAZIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT8683</td>
<td>Neurodegeneration (eIF2β activator)</td>
<td>Bristol Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPM2003</td>
<td>Pemphigus Vulgaris (ND)</td>
<td>Topas Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT7001</td>
<td>Oncology (CDK7)</td>
<td>Carnick</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT7001</td>
<td>Oncology (CDK7)</td>
<td>Carnick</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APN411</td>
<td>Oncology – Immunotherapy</td>
<td>SANOFI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAYxxxx</td>
<td>Nephrology (not disclosed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QRB001</td>
<td>Metabolic – Diabetes (not disclosed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVT075</td>
<td>Covid-19 / HBV</td>
<td>n.a.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not disclosed</td>
<td>Various programmes</td>
<td>Bristol Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVTxxxx</td>
<td>CNS, Metabolic, Pain, ...</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Multiple programmes across nephrology, oncology, immunology among other therapeutic areas
EVOequity continues co-owning strategy

Operational VC model – diversified portfolio with multiple shots on goal

At Equity Holding (≥20%) or Significant influence

Minority Shareholdings (<20%)

BRIDGEs

Starting points to fuel EVOequity portfolio

Attractive portfolio with significant upside

External deal-flow

Academia & BRIDGEs

Partners

Evotec spin-outs

Portfolio companies

http://actionplan.evotec.com/evoequity
Guidance confirmed – On track towards reaching AP 2025 goal

Guidance 2022

<table>
<thead>
<tr>
<th></th>
<th>Guidance 2022</th>
<th>YE 2021</th>
<th>Implied growth at midpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group revenues (H1 2022)</td>
<td>€ 715 – 735 m</td>
<td>€ 618 m</td>
<td>&gt;15%</td>
</tr>
<tr>
<td>(at constant fx-rates(^{1)})</td>
<td>(€ 690 – 710 m)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unpartnered R&amp;D(^{2)})</td>
<td>€ 70 – 80 m</td>
<td>€ 58 m</td>
<td>~30%</td>
</tr>
<tr>
<td>Adjusted EBITDA(^{3)})</td>
<td>€ 105 – 120 m</td>
<td>€ 107 m</td>
<td>At least stable</td>
</tr>
<tr>
<td>(at constant fx-rates(^{3)}); H1 2022)</td>
<td>(€ 85 – 100 m)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{1)}\) EUR/US$ 1.18; EUR/GBP 0.86
\(^{2)}\) No material fx effects as most R&D efforts are carried out in € area
\(^{3)}\) Excluding M&A related costs (€ -5 m ytd) and before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result
Strong finish to the year needed and anticipated

EBITDA bridge 9M 2022 – FY 2022 guidance target

in € m

- Visible contribution from milestones, upfronts & licenses
- Excellent base business with strong operating leverage
- Acceleration of Just – Evotec Biologics revenues leading to very strong operating leverage
- Minor tailwind from fx-rates
- M&A costs not part of initial guidance

<table>
<thead>
<tr>
<th>EBITDA 9M 2022</th>
<th>Milestones, Upfronts, Licenses</th>
<th>Base business</th>
<th>Just – Evotec Biologics</th>
<th>Other</th>
<th>EBITDA 2022E</th>
</tr>
</thead>
<tbody>
<tr>
<td>46.4 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;105</td>
</tr>
</tbody>
</table>

1) Excluding M&A costs composing of transaction costs and earnings impact related to acquisitions of Rigenerand (“Evotec Modena Srl”) and Central Glass, Halle (“Evotec DS”)
2) fx-effect/M&A costs
Clear strategy in place

Growth and investment strategy overview – Action Plan 2025

Targeted revenue development (in € m)
- CAGR ~15%
- 2020: 501
- 2021: 618
- 2022 (e): 2023 (e): 2024 (e): 2025 (e): >1,000

Revenue composition 2020
- EVT Execute
- Just – Evotec Biologics
- EVT Innovate

Goal revenue composition
- Ent-to-end shared R&D
- Just - Evotec Biologics
- PanOmics
- iPSC based cell therapy

- Composition of revenue mix expected to change over time while ALL fields continue to grow
- Shifting to even more favourable revenue mix expected to drive increased profitability
- Just – Evotec Biologics growth driven by use of J.POD® manufacturing
- First small royalties from pipeline assets expected in 2025

1) Just – Evotec Biologics reports under the EVT Execute segment
## Executing to accelerate growth along Action Plan 2025

### Selected major newsflow 2022

| R&D efficiency platforms | • Undisrupted growth of base business, in-line with AP 2025 (**EVOiR&D**)  
| | • New integrated drug discovery & development alliances  
| | • Significant capacity and value chain expansion for all modalities |

| Precision medicine platforms | • New strategic partnerships and expansions of co-owned alliances  
| | • New clinical trial initiations  
| | • Significant progress of later stage co-owned pipeline (**EVOroyalty**)  
| | • Spin-Offs and investments along Building Blocks of AP 2025 (**EVOequity**) |

| Just – Evotec Biologics | • Start of production **J.POD®** Redmond, WA (US)  
| | • Start of construction **J.POD®** Toulouse, France (EU)\(^1\)  
| | • Evaluation of global network of **J.PODs®** (**EVOaccess**) |

| Group & ESG | • Undisrupted growth trend versus 2021 in line with AP 2025  
| | • Growth of unpartnered R&D investments faster than top-line  
| | • Validated science-based targets aligned with 1.5°C goal  
| | • Highly impactful contribution to UN SDG 3\(^2\) |

---

\(^1\)This project benefits from French government funding as part of the Investments for the future Programme (programme d'investissements d'avenir in French) and is also supported economically by the Occitanie Region and Toulouse Métropole.

\(^2\)UN Sustainable Development Goal 3: Improve health and well-being with main targets for us on women’s health, fight against infectious diseases and pandemic preparedness
# Upcoming important dates

## Financial calendar 2023

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary FY 2022 results</td>
<td>28 March 2023</td>
</tr>
<tr>
<td>Full year 2022 report</td>
<td>25 April 2023</td>
</tr>
<tr>
<td>Quarterly Statement Q1 2023</td>
<td>10 May 2023</td>
</tr>
<tr>
<td>Virtual Annual General Meeting 2023</td>
<td>20 June 2023</td>
</tr>
<tr>
<td>Half-year 2023 Interim Report</td>
<td>09 August 2023</td>
</tr>
<tr>
<td>Quarterly Statement 9M 2023</td>
<td>08 November 2023</td>
</tr>
</tbody>
</table>
Appendix
Action Plans deliver significant value

Action Plans in numbers - “... we are just at the beginning”

2009
Action Plan 2012
Restructure for growth

2010
- Revenues: € 55 m
- Adj. EBITDA: € 2 m
- R&D investments:1) € 2 m
- Co-owned projects: 6
- Employees: 519

2012
Action Plan 2016
Build innovation seeds

2015
- Revenues: € 128 m
- Adj. EBITDA: € 9 m
- R&D investments:1) € 18 m
- Co-owned projects: 49
- Employees: 1,000

2018
Action Plan 2022
Aspire global leadership

2020
- Revenues: € 501 m
- Adj. EBITDA: € 107 m
- R&D investments:1) € 69 m
- Co-owned projects: 118
- Employees: 3,572

2021
Action Plan 2025
Leadership in data, science, multimodality & access

2025

1) Including equity investments
Platforms and panomics technologies for more precision and efficiency

Evotec today – 17 Sites and more than 4,500 employees

USA
>500
• Branford
• Princeton
• Redmond, WA
• Seattle
• Watertown

Austria
~40
• Orth an der Donau

Italy
>850
• Verona (Campus Levi-Montalcini)
• Modena

Germany
>1,150
• Hamburg (HQ) & Goettingen (Manfred Eigen Campus)
• Cologne
• Halle/Westfalen
• Munich

UK
>950
• Abingdon (Dorothy Crowfoot Hodgkin Campus)
• Alderley Park

France
>950
• Lyon
• Toulouse (Campus Curie)

1) This project benefits from French government funding as part of the Investments for the future Programme (programme d'investissements d'avenir in French) and is also supported economically by the Occitanie Region and Toulouse Métropole.
Great talent pool
Overview Employees – more than 4,500

Interdisciplinary
- Biochemists
- Medicinal chemists
- Molecular biologists
- Cell biologists
- Toxicologists
- Data scientists
- Process/Analytical chemists
- Clinicians
- mAb process engineers

International\(^1\)
- 22% Others
- 20% German
- 21% French
- 19% Italian
- 18% British

Highly qualified
- 76% with at least one academic qualification
- 24% other degrees

Diverse and experienced
- 84 nationalities
- >30% PhDs
- Average age: 38.5 years
- 54% women
- > 36% with more than five years at Evotec

\(^1\) The chart exclude the USA for legal reasons
Strong team and shareholders supporting sustainable growth

Management & shareholder structure 1)

Management Board
- Werner Lanthaler (CEO)
  Long-time experience in Pharma & biotech
- Cord Dohrmann (CSO)
  Long-time experience in drug discovery
- Matthias Evers (CBO)
  Long-time experience in business development, technology and strategy
- Craig Johnstone (COO)
  Strong drug discovery and commercial track record
- Enno Spillner (CFO)
  Long-time experience in finance & biotech

Supervisory Board
- Iris Löw-Friedrich
  UCB
- Camilla Macapili Languille
  Mubadala Investment Co.
- Mario Polywka
  Ex-Evotec
- Roland Sackers
  QIAGEN
- Elaine Sullivan
  Ex-Lilly
- Constanze Ulmer-Eilfort
  PSP Munich

Number of shares: 177.0 m
Listings: Frankfurt Stock Exchange (MDAX, TecDAX), Ticker: EVT
          NASDAQ Global Select Market (ADS), Ticker: EVO
52 week high/low: € 44.94/€ 15.77

1) Rounding differences may occur
Your contact:

Volker Braun  
*SVP Head of Global Investor Relations & ESG*  
+49.(0).40.560 81-775  
+49.(0).151 1940 5058 (m)  
volker.braun@evotec.com